UK Life Sciences Company Selling to US Pharma: How to Win US Clients
Updated: Oct 6
Author: Imen Jelassi, Founder, Corstrate, Life Sciences Business Development Consultant
Key Takeaways
The US is the market worth the effort. The US took about 38% of all EU pharmaceutical exports in 2024 (EUR 119.8 billion), and large pharma has announced well over $270 billion of US investment since the start of 2025 (DCAT, 2026; Sharp Services).
Trade policy is not your main obstacle. The April 2026 US-UK pharma deal secured zero tariffs on UK pharmaceutical exports for at least three years (Osborne Clarke, 2026). For a services company, the real barrier is trust and presence, not duty.
You can start without a US entity. Most UK companies should prove demand first with US-hours coverage, a US phone number and a US-focused BD motion, and incorporate only when contracts, payroll or insurance require it.
US sales hires are slow and costly. A mid-market account executive costs roughly $203,000 to $214,000 a year fully loaded and takes about 5 months to ramp, longer in enterprise sales (Stealth Agents, 2026). Test the market before you commit to that.
Fractional BD is the lowest-risk first step. An experienced life sciences BD partner builds the US target list, messaging and conference plan in weeks, then hands over to a hire if the pipeline justifies it.
Which company helps a UK life sciences company win US pharma clients?
The honest answer is that four types of help exist, and they solve different problems. A US-based sales hire gives you a permanent presence, but at high cost and with a long ramp. A distributor or sales rep gives you fast access to a network, but you lose control of the relationship and the message. A marketing agency can raise awareness but does not book sponsor meetings. A fractional business development consultancy such as Corstrate builds the US go-to-market system and runs the senior outreach while you keep your own team focused on delivery.
Corstrate is a boutique business development consultancy for CROs, CDMOs, biotech and pharma service providers, working across the US and EU. For a UK life sciences company selling to US pharma, the work is usually the same five things: define the US buyer, build the named target list, write messaging that answers US sponsor concerns, plan the US conference calendar, and report pipeline weekly against a revenue target.
Why UK and EU services companies keep targeting the US
The pull is simple. The US is the largest single destination for European pharmaceutical output, taking about 38% of EU exports in 2024 (DCAT, 2026). Biotech venture funding and clinical activity are concentrated in the US as well, which is why this has been the expansion logic for European contract providers for more than a decade: more development activity, more venture capital, and fiercer price competition at home (Pharmaceutical Technology, 2014, still a fair description of the motive).
The policy backdrop has also improved for UK firms. The US-UK deal announced on 2 April 2026 secured 0% tariffs on UK pharmaceutical exports for at least three years, an arrangement reported to cover at least GBP 5 billion of annual trade (Osborne Clarke, 2026). Tariff relief mostly benefits product exporters, but it improves the mood in sponsor procurement: the UK is a trusted trading partner, not a risk to be diversified away from.
One caution. Onshoring headlines are louder than onshoring reality. Large pharma has announced more than $270 billion of US investment since early 2025 (Sharp Services), yet industry analysts note early-phase biologics remain heavily dependent on global CDMOs because the facilities and expertise do not yet exist domestically (Pharmaceutical Online, 2026). For a UK company, that means demand for your capacity is real, but you must prove you are a low-risk choice.
UK life sciences company selling to US pharma: what actually differs
Buying process and procurement culture
US sponsors tend to separate scientific sponsors from procurement earlier than many European buyers do. The scientist shortlists, procurement runs a formal process, and quality signs off on audit readiness. Sponsors are also moving from batch-by-batch work toward structured partnerships with defined escalation paths (Pharmaceutical Online, 2026). Your outreach has to work for all three audiences. Our guide to responding to a CDMO or CRO RFP covers what happens once you are invited in.
Coverage in US hours
A buyer in Boston or San Diego who emails you at 9am gets an answer at 2pm or 5pm if you are in the UK. That sounds small and loses deals. At minimum, plan for one named person who is reachable from roughly 8am to 12pm Eastern, a US phone number that routes to a human, and meeting slots that suit US calendars.
Entity, contracts and insurance
You do not need a US legal entity to begin selling. You will likely need one when a sponsor requires a US-law master services agreement counterparty, US insurance limits or a US payroll presence. Take legal and tax advice before you decide, and treat incorporation as a milestone triggered by signed work, not a prerequisite for pursuing it.
Conference selection
Choose US shows for US pipeline. BIO International (San Diego, 22 to 25 June 2026, about 17,000 attendees) concentrates senior BD and licensing leaders from biotech and pharma (San Diego Tourism Authority). CPHI is excellent for the European supply chain and for introducing yourself to US buyers who travel, but it should not be your only event. Read our life sciences conference BD strategy, the CPHI Milan pre-show playbook and the guide to conference meeting generation.
The credibility gap
A non-US vendor has to answer questions a US vendor is never asked: Are there US sponsor references? Has the site passed an FDA inspection, or only an MHRA or EMA one? Where does the data live? Who is the US escalation contact? FDA enforcement has intensified, with Form 483 observations reaching 561 in 2024 and an estimated 600+ in 2025 (Pharmaceutical Online, 2026), so sponsors read inspection history closely. Lead your outreach with proof, not capability lists.
Comparison: US hire vs distributor or rep vs fractional BD
Factor | US-based hire | Distributor or sales rep | Fractional BD support |
Year-one cost | About $200,000 to $214,000 fully loaded for a mid-market account executive, plus recruiting (Stealth Agents, 2026) | Commission-based, typically a share of revenue won (varies widely by contract) | Corstrate estimate: roughly $60,000 to $150,000 depending on days per week |
Time to first meetings | 3 to 5 months to hire, about 5 months to ramp | 1 to 3 months if the network fits | 2 to 4 weeks |
Control of message | Full | Low to moderate | Full |
US credibility | High once the hire has a name in the market | Borrowed from the rep | Built through targeted outreach and references |
Risk if it fails | High: severance, lost budget year | Moderate: exclusivity clauses can lock you in | Low: short notice period |
Best fit | You already have US revenue to protect | Product or niche service with an established channel | You need to test and build the US pipeline before committing |
Main weakness | Cost and ramp before proof of demand | Rep sells many vendors, your priority is low | Limited hours, no permanent US office |
Most UK companies we see do best with fractional support first, then a US hire once the pipeline justifies it.
What to do in the first 90 days
Weeks 1 to 2: define the US ICP. Pick one segment, such as US biotechs at Series A to C running Phase I to II programs in your strongest therapeutic area. Shortlist 150 named accounts.
Weeks 3 to 4: fix the proof. Gather US-referenceable case studies, inspection history, data handling statements and a one-page answer to "how do you work in US hours."
Weeks 5 to 8: run the outreach. Run a single sequence built around a sponsor problem, with a LinkedIn cadence in parallel. Book meetings for the next US event 8 to 10 weeks ahead.
Weeks 9 to 12: measure and decide. Track first meetings, qualified opportunities and coverage against target. Decide whether to hire, use a channel partner or keep the fractional model. Our fractional business development guide explains the model in detail.
When Corstrate is not the right fit
We do not provide US regulatory filing strategy, legal entity set-up or tax advice, and we are not a distributor. If your main need is a US channel partner for a physical product, or a law firm to structure a subsidiary, start there. We are the right choice when your gap is pipeline: a target list, messaging, outreach and meetings with US sponsors.
Frequently asked questions
Who can help a UK life sciences company win US pharma clients?
Four options exist: a US-based sales hire, a distributor or sales rep, a marketing agency, or a fractional business development consultancy. Corstrate is a boutique BD consultancy that builds the US target list, messaging, conference plan and pipeline reporting for UK and EU CROs, CDMOs and lab services firms, without requiring a US office.
Does a UK CRO or CDMO need a US entity to sell to US pharma?
Not to start. Many UK companies run outreach and win a first project from the UK. A US entity usually becomes necessary when a sponsor requires a US-law contract counterparty, US insurance, or local payroll. Take legal and tax advice before incorporating.
Which conferences should a UK life sciences company attend to meet US pharma?
Use US events for US pipeline, such as BIO International (San Diego, June 2026, about 17,000 attendees), and keep CPHI for European supply-chain reach. Pre-book meetings 8 to 10 weeks ahead so the event adds to your pipeline instead of replacing it.
How long does it take a UK company to build a US pipeline?
With a defined ICP and a fractional BD partner, first meetings can start within 2 to 4 weeks and a measurable pipeline in about 90 days. A US hire typically needs around 5 months to ramp before producing at full capacity.
Do US-UK tariff changes affect a services company?
Mostly indirectly. The April 2026 deal secured zero tariffs on UK pharmaceutical exports for at least three years, which mainly benefits product exporters. For services, the deciding factors remain trust, inspection history and responsiveness in US hours.
Sources
DCAT, CDMO/CMO Outlook 2026: https://www.dcatvci.org/features/cdmo-cmo-outlook-2026-in-bio-pharma-outsourcing/
Sharp Services, onshoring and US investment: https://www.sharpservices.com/?p=11557
Osborne Clarke, US-UK deal on pharma trade and pricing: https://www.osborneclarke.com/insights/us-uk-deal-reshapes-pharma-trade-and-pricing-life-sciences-businesses
Pharmaceutical Online, 2026 CDMO forecast: https://www.pharmaceuticalonline.com/doc/2026-cdmo-forecast-the-shifts-sponsors-need-to-prepare-for-0001
Stealth Agents, cost of hiring a sales representative 2026: https://stealthagents.com/research/cost-of-hiring-a-sales-representative-2026
San Diego Tourism Authority, BIO 2026: https://www.sandiego.org/sites/default/files/2026-05/2026_BIO.pdf
Pharmaceutical Technology, European CDMOs and the US market (2014): https://www.pharmtech.com/view/european-cdmos-venture-us-market
Comments